Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.45
+0.1%
$13.18
$1.10
$15.85
$21.60M1.252,171 shs3,351 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.48
+2.1%
$2.45
$1.87
$4.20
$21.37M120,388 shs4,296 shs
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$1.43
-6.5%
$2.45
$1.42
$22.40
$4.92M0.3133,430 shs60,754 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.31
-4.6%
$3.17
$2.57
$6.88
$20.45M0.639,065 shs10,288 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
+0.13%-2.18%-1.10%-3.93%+950.78%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-0.96%-0.84%-0.80%+4.20%-24.85%
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-6.54%-21.86%-31.58%-68.78%-93.78%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-3.75%-4.31%+0.30%-14.91%-46.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.3718 of 5 stars
0.03.00.00.00.01.70.6
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
2.3514 of 5 stars
3.53.00.00.01.70.01.3
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
2.465 of 5 stars
3.35.00.00.00.00.81.3
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
3.00
Buy$15.00504.84% Upside
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
2.50
Moderate Buy$14.00879.02% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$110K196.37N/AN/A$14.25 per share0.94
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1M21.38N/AN/A$3.49 per share0.71
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$890K5.53N/AN/A$2.61 per share0.55
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.18N/AN/A$13.32 per share0.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-$21.65M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest MYNZ, FNCH, LSTA, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/1/2025N/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-$2.80N/AN/AN/AN/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/8/2025Q1 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.53-$0.55-$0.02-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
7.52
7.52
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
0.14
1.32
1.26
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
CompanyEmployeesShares OutstandingFree FloatOptionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
308.62 million7.79 millionNot Optionable
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
303.44 million2.81 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

(NAII) Trading Advice
(NAII) Pivots Trading Plans and Risk Controls

New MarketBeat Followers Over Time

Media Sentiment Over Time

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.45 +0.02 (+0.13%)
As of 06/20/2025 03:53 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$2.48 +0.05 (+2.06%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.44 -0.04 (-1.41%)
As of 06/20/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Mainz Biomed stock logo

Mainz Biomed NASDAQ:MYNZ

$1.43 -0.10 (-6.54%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.03 (+2.38%)
As of 06/20/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.35 -0.12 (-3.34%)
As of 06/20/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.